Hyphens Pharma International Past Earnings Performance
Past criteria checks 2/6
Hyphens Pharma International has been growing earnings at an average annual rate of 11.5%, while the Pharmaceuticals industry saw earnings growing at 11.4% annually. Revenues have been growing at an average rate of 7.6% per year. Hyphens Pharma International's return on equity is 13%, and it has net margins of 5%.
Key information
11.5%
Earnings growth rate
11.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 7.6% |
| Return on equity | 13.0% |
| Net Margin | 5.0% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Hyphens Pharma International makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 171 | 9 | 50 | 0 |
| 30 Sep 23 | 156 | 7 | 48 | 0 |
| 30 Jun 23 | 156 | 9 | 48 | 0 |
| 31 Mar 23 | 156 | 10 | 48 | 0 |
| 31 Dec 22 | 162 | 11 | 48 | 0 |
| 30 Sep 22 | 156 | 12 | 40 | 0 |
| 30 Jun 22 | 143 | 9 | 43 | 0 |
| 31 Mar 22 | 132 | 8 | 40 | 0 |
| 31 Dec 21 | 126 | 7 | 40 | 0 |
| 30 Sep 21 | 126 | 6 | 37 | 0 |
| 30 Jun 21 | 123 | 6 | 39 | 0 |
| 31 Mar 21 | 126 | 6 | 37 | 0 |
| 31 Dec 20 | 121 | 6 | 37 | 0 |
| 30 Sep 20 | 126 | 7 | 36 | 0 |
| 30 Jun 20 | 125 | 8 | 36 | 0 |
| 31 Mar 20 | 124 | 7 | 35 | 0 |
| 31 Dec 19 | 119 | 7 | 35 | 0 |
| 30 Sep 19 | 117 | 6 | 33 | 0 |
| 30 Jun 19 | 115 | 5 | 32 | 0 |
| 31 Mar 19 | 117 | 5 | 32 | 0 |
| 31 Dec 18 | 121 | 5 | 31 | 0 |
| 30 Sep 18 | 117 | 5 | 32 | 0 |
| 30 Jun 18 | 117 | 6 | 30 | 0 |
| 31 Mar 18 | 115 | 6 | 29 | 0 |
| 31 Dec 17 | 113 | 6 | 29 | 0 |
| 31 Dec 16 | 101 | 5 | 29 | 0 |
| 31 Dec 15 | 78 | 5 | 19 | 0 |
Quality Earnings: 1J5 has high quality earnings.
Growing Profit Margin: 1J5's current net profit margins (5%) are lower than last year (7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1J5's earnings have grown by 11.5% per year over the past 5 years.
Accelerating Growth: 1J5's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 1J5 had negative earnings growth (-24.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (8.7%).
Return on Equity
High ROE: 1J5's Return on Equity (13%) is considered low.